Imagine a world where a single pill could revolutionize the way we tackle obesity, sparking both hope and heated debates. That’s exactly what’s happening with Novo Nordisk’s Wegovy pill, which sent the company’s shares soaring 5% after a promising U.S. launch. But here’s where it gets controversial: can this pill truly outshine its competitors, or is the hype premature? Let’s dive in.
On January 15, 2026, a pharmacist in Provo, Utah, proudly displayed a box of Wegovy pills, marking a significant moment in the fight against obesity. Early prescription data revealed an encouraging start for this GLP-1 pill, the first of its kind designed for weight loss. TD Cowen analysts labeled it a ‘solid start,’ but they were quick to caution: ‘One data point does not make a trend.’ The pill officially launched on January 5, 2026, after gaining approval in late December, and while the initial numbers are promising, analysts stress the need for more data to fully understand its market potential.
And this is the part most people miss: Novo Nordisk isn’t just competing against obesity—it’s battling its arch-rival, Eli Lilly, for dominance in the booming obesity and diabetes drug market. Eli Lilly seized the majority market share in early 2025 and is hot on Novo Nordisk’s heels with its own oral obesity drug set to launch soon. The stakes are high, and every prescription counts.
According to Leerink Partners analyst David Risinger, Wegovy racked up around 3,100 prescriptions in its first week, citing IQVIA data for the week ending January 9. In comparison, Eli Lilly’s popular obesity injection, Zepbound, managed about 1,300 prescriptions in its first week and roughly 8,000 in the second. But here’s the twist: TD Cowen analysts, using Symphony data via Bloomberg, reported slightly higher numbers—around 4,290 prescriptions for Wegovy in its first full week, mostly for the starting dose. They noted that these figures likely exclude prescriptions from Novo Nordisk’s direct-to-consumer pharmacy and telehealth partners, which could skew the data.
Bold claim alert: If the Symphony data holds up, Wegovy is already outperforming its injectable counterparts at this stage. However, TD Cowen’s Michael Nedelcovych warns that a direct comparison between pills and injections may not be fully clear until early next week, and even then, we might need another two to three quarters for a complete picture. He’s particularly interested in the direct-to-consumer channel, which he believes holds ‘significant promise’ for Wegovy’s success.
But the plot thickens. Eli Lilly’s upcoming pill, orforglipron, is expected to hit the market in the coming months, potentially shifting demand. While Wegovy has a head start, it’s a peptide medication with dietary restrictions—no food or drink for 30 minutes after taking it—which could limit its appeal. In contrast, Eli Lilly’s pill is a small molecule drug with no such restrictions, making it a potentially more convenient option.
Here’s the burning question: Will Wegovy’s early success translate into long-term dominance, or will Eli Lilly’s pill steal the spotlight? And what role will consumer preferences and convenience play in this high-stakes race? Share your thoughts in the comments—this is one debate you won’t want to miss!
